Výsledky vyhledávání - "Sylvie G Laquerre"

Akademický článek

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

Autor: Alastair J King, Marc R Arnone, Maureen R Bleam, Katherine G Moss, Jingsong Yang, Kelly E Fedorowicz, Kimberly N Smitheman, Joseph A Erhardt, Angela Hughes-Earle, Laurie S Kane-Carson, Robert H Sinnamon, Hongwei Qi, Tara R Rheault, David E Uehling, Sylvie G Laquerre

Publikováno v: PLoS ONE, Vol 8, Iss 7, p e67583 (2013)

Mitogen-Activated Protein Kinase (MAPK) pathway activation has been implicated in many types of human cancer. BRAF mutations that constitutively activate MAPK signalling and bypass the need for upstream stimuli occur with high prevalence in melanoma,

Externí odkaz: https://doaj.org/article/f2ff4fc2ea6640b3bec689c5d38dc373

Zobrazit plný text záznamu

Supplementary Methods, Table 1, Figures 1-9 from Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

Autor: Tona M. Gilmer, Li Liu, Sylvie G. Laquerre, Scott H. Dickerson, Kimberly N. Smitheman, Ashley M. Hughes, Maureen R. Bleam, Vivian Zhang, Stephen D. Eastman, James G. Greger

PDF file - 276K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612cd6282bf70c0b319d1c53a2e6856c
https://doi.org/10.1158/1535-7163.22499103.v1

Zobrazit plný text záznamu

Data from Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

Autor: Tona M. Gilmer, Li Liu, Sylvie G. Laquerre, Scott H. Dickerson, Kimberly N. Smitheman, Ashley M. Hughes, Maureen R. Bleam, Vivian Zhang, Stephen D. Eastman, James G. Greger

Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown encouraging response rates; however, the duration of response has been limited. To identify determinants of acquired resistance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::342d7af81845cc3449fb50863d2f5fa4
https://doi.org/10.1158/1535-7163.c.6536067

Zobrazit plný text záznamu

Supplementary Data from GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Autor: Sylvie G. Laquerre, David Sutton, Roland Annan, Francesca Zappacosta, Jingsong Yang, Kelly E. Fisher, Symon Erskine, Cynthia M. Rominger, Swarupa G. Kulkarni, Elisabeth A. Minthorn, Katherine G. Moss, Arthur Groy, Maureen R. Bleam, Aidan G. Gilmartin

Supplementary Figures S1-S6.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7058b2fa24465f2173cd06088172f582
https://doi.org/10.1158/1078-0432.22443324.v1

Zobrazit plný text záznamu

Data from GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Purpose: Despite their preclinical promise, previous MEK inhibitors have shown little benefit for patients. This likely reflects the narrow therapeutic window for MEK inhibitors due to the essential role of the P42/44 MAPK pathway in many nontumor ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d39348d02bb57cb5edbc2432031aee
https://doi.org/10.1158/1078-0432.c.6519777

Zobrazit plný text záznamu

Supplementary Tables 1-3 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Autor: Sylvie G. Laquerre, Jeffrey R. Jackson, Melody A. Diamond, David Sutton, Mary P. Courtney, Richard R. Gontarek, Gary K. Smith, Daniel F. Hassler, Lenore Madden, Ryan G. Kruger, Symon G. Erskine, Mark C. Richter, Maureen R. Bleam, Aidan G. Gilmartin

Supplementary Tables 1-3 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63807349d8c5365b462bb33763b38e0
https://doi.org/10.1158/0008-5472.22378532.v1

Zobrazit plný text záznamu

Supplementary Figure Legends 1-4 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Supplementary Figure Legends 1-4 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680e0f17f3ce8cc74f754d82f38def5e
https://doi.org/10.1158/0008-5472.22378538.v1

Zobrazit plný text záznamu

Supplementary Figures 1-4 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Supplementary Figures 1-4 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ad8ebae32a794098ee99c407b72872
https://doi.org/10.1158/0008-5472.22378535.v1

Zobrazit plný text záznamu

Additions to Supplement Table 3 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Additions to Supplement Table 3 from Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2382019a7bca7fdff5e1920fcfcedfa6
https://doi.org/10.1158/0008-5472.22378544.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání